Aren't there any 2nd generation nukes in development for HIV that could supercede tenofovir disoproxil and emtricitabine in a more potent combo formulation (and then add in a better PI than Sustiva)?
Wouldn't this be a pretty good way to break Gilead's stranglehold on the market?
Market Data 
Markets 
AI
